Financial Data and Key Metrics Changes - Fourth quarter revenue for 2025 reached $62.1 million, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history [4][15] - Full year revenue for 2025 was $201.5 million, a 1% increase compared to 2024, with a notable turnaround in the second half of the year where revenue grew by 5% compared to the second half of 2024 [7][25] - GAAP gross profit for Q4 was $32.9 million, a 2% decline from $33.7 million in Q4 2024, with a gross profit margin of 53% compared to 59% in the prior year [18][19] - Net loss for Q4 was $44.1 million, compared to net income of $9.6 million in the prior year quarter, primarily due to a $38.1 million valuation allowance against deferred tax assets [22][30] Business Line Data and Key Metrics Changes - Instrument revenue grew 22% in 2025, with a 26% increase in Q4 compared to the prior year [9] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year 2025, driven by improvements in delivery times and a large catalog of products [10][17] - Service revenue grew 25% in Q4 year-over-year, supported by an expanding installed base and active usage of systems [17] Market Data and Key Metrics Changes - EMEA and APAC regions posted double-digit year-over-year revenue growth in Q4, with EMEA driven by strong instrument demand from academic and government customers [5][15] - U.S. revenue saw mid-single digit growth in Q4, driven by academic and government market sentiment, but was offset by declines in biotech and pharma instrument sales [6][15] Company Strategy and Development Direction - The company aims to reinforce its market leadership in next-gen cell analysis solutions through strategic pillars: instrument, application, bioinformatics, and clinical [8] - The focus remains on driving market penetration of instrument platforms, advancing technological leadership, and growing recurring revenue lines [35] Management's Comments on Operating Environment and Future Outlook - Management noted a stabilization in the market environment, with expectations for continued growth in 2026, particularly in service and reagent businesses [14][33] - The company anticipates a revenue outlook for 2026 between $205 million and $212 million, reflecting improved market conditions in EMEA and the U.S. [33] Other Important Information - The company established a new manufacturing facility in Singapore, which began generating revenue within 100 days of build-out, enhancing its operational resilience [12] - Cash and marketable securities totaled $261.5 million as of December 31, 2025, reflecting a decrease from the previous year due to stock repurchase activities [32] Q&A Session Summary Question: What drove the end-of-year growth acceleration? - Management indicated that the growth was driven by a normalization in academic and government spending, along with catch-up disbursements from the NIH [44] Question: What was the mix in 2025 between new customer acquisitions versus existing customers expanding their capacity? - Management noted that the growth was a combination of both new customer acquisitions and existing customers purchasing additional systems [52] Question: How is the company thinking about commercial investments in 2026? - The company plans to continue investing in high-end market segments and in its reagent sales force to drive future revenue growth [54][55]

Company Overview - Cytek is a cell analysis company recognized for empowering scientific discovery in its field [3] - The company has been named one of the fastest-growing companies by Time Magazine and received accolades such as Company of the Year by the Chronicle Journal [3] Product and Achievements - Since launching its first instrument in 2016, Cytek has delivered over 3,000 instruments [4] - More than 3,000 technical journals have cited Cytek's technology as instrumental in their discovery work [4]

Cytek Biosciences FY Conference Summary Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Cell analysis and flow cytometry - **Recognition**: Named one of the fastest growing companies by Time Magazine and awarded Company of the Year by Clinical Leader and the Journal [2][3] Financial Performance - **Revenue**: Reported $201 million for FY 2025, slightly above the previous year [3] - **Cash Position**: $262 million by the end of Q3 2025 [3] - **Q4 Revenue**: $62 million, with a quarter-to-quarter growth trend showing recovery [17][18] - **Growth Rates**: - Q1: -8% YoY - Q2: -2% YoY - Q3: 2% YoY - Q4: 8% YoY [17][18] Market Dynamics - **Market Size**: The overall market opportunity is projected to be $5.1 billion by 2025, with a CAGR of 8.8% through 2032 [4][5] - **Revenue Sources**: - 59% from biotech and pharma - 41% from academic and government-supported agencies [4] - **Geographic Revenue Breakdown**: - 50% from the U.S. - 26% from APEC (including China) - 24% from other regions [4] Business Model and Strategy - **Five Business Pillars**: Instruments, applications, bioinformatics, clinical, and reagents [5] - **Reagent Business**: Focus on expanding reagent sales, with a growth of over 20% in 2025 [30] - **Cytek Cloud**: Over 20,000 users, providing automated panel optimization and data management [6][7] - **Clinical Applications**: Instruments approved for clinical use in China and Europe, targeting applications like leukemia MRD [8][9] Competitive Positioning - **Market Share**: Growth attributed to capturing market share from competitors, especially in a challenging market environment [26][28] - **Product Portfolio**: Broad range of cell analysis tools, including the new Aurora EVO, which has been well-received [11][12][20] - **Innovation Focus**: Continuous investment in R&D to drive product innovation and maintain leadership in flow cytometry [19][21] Future Outlook - **Growth Projections**: Anticipated substantial growth in 2026, driven by an increased installed base and stabilization in North America and EMEA [28][22] - **Recurring Revenue Potential**: Significant opportunities in reagents and services, with low current market penetration [32][33] - **M&A Strategy**: Balanced approach to capital allocation, focusing on share repurchase and opportunistic acquisitions [35] Key Takeaways - **Technology Leadership**: Cytek is positioned as a leader in flow cytometry, with essential tools for life sciences [23][37] - **Global Diversification**: Manufacturing and sales operations across multiple continents, enhancing resilience [24] - **Positive Cash Flow**: One of the few life science tool companies generating positive cash flow [25] Conclusion Cytek Biosciences is well-positioned for continued growth and profitability, supported by a strong product portfolio, innovative technology, and a strategic focus on expanding its market share and recurring revenue streams [38]